Please login to the form below

Not currently logged in

ABPI appoints head of commercial affairs

Carol Blount has joined the Association of the British Pharmaceutical Industry as head of commercial affairs

Carol Blount has joined the Association of the British Pharmaceutical Industry (ABPI) as head of commercial affairs.

She joins the ABPI with more than 15 years' senior level leadership experience within UK pharma including leadership of strategic innovation and change, business development and brand marketing. She has worked previously for Bayer and AstraZeneca.


Carol Blount
Carol Blount


In her new role, she is responsible for managing all commercial affairs and initiatives within the ABPI, including NHS Joint Working and quality innovation, prevention and productivity (QIPP) initiatives, delivery of commercial aspects of Pharmaceutical Price Regulation Scheme (PPRS), supply chain and distribution initiatives.

Carol commented: "With a new government and an uncertain financial situation throughout the world, these are challenging times for our industry. I am very much looking forward to working in my new role to help tackle some of the vitally important issues facing the industry."

Alison Clough, ABPI Commercial and Communications director said: "I am delighted that Carol is joining our strengthened commercial team. Her extensive experience will bring added value to our activities working with the NHS on QIPP, as well as supply shortages and other commercial issues."

15th June 2010


Featured jobs

Subscribe to our email news alerts


Add my company

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...